In the following, the generic term ‘preventive option or measure’ applies to all measures that can be offered to women with BRCA1/2 mutations either to reduce the risk of breast or ovarian cancer or for breast cancer screening. This evidence concerns the gene BRCA1 and breast carcinoma.